Central Nervous System

BlueSkeye AI to begin trial of AI mental health app for perinatal depression

The Medical and Healthcare products Regulatory Agency (MHRA) has greenlit BlueSkeye AI to begin a clinical trial investigating its TrueBlue…

Boston Scientific acquires Relievant Medsystems for $850m

Boston Scientific has concluded the acquisition of Relievant Medsystems for an upfront cash payment of $850m. The deal also includes…

Medicare sets preliminary payment for ReWalk’s personal exoskeleton

The Centers for Medicare & Medicaid Services (CMS) in the US has set a preliminary payment determination of $94,617 for…

Neurovalens wins FDA clearance for insomnia device

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Neurovalens’s Modius Sleep, a device used to treat…

AC Immune publishes data showing diagnostic activity of a-syn PET tracer in MSA

AC Immune has published data on its alpha-synuclein (a-syn) positron emission tomography (PET) tracer, ACI-12589, which showed the compound’s ability…

IntellexxDNA tests clinical decision support tool for dementia management

IntellexxDNA has been cleared by the US Institutional Review Board (IRB) to start a study for its clinical decision support…

Thought-driven movement device for spinal injuries implanted in first human

ONWARD Medical has completed the first-in-human implant of its spinal cord stimulator with use of an investigational brain computer interface…

SpineX receives funds to complete trial of SCiP device for cerebral palsy

SpineX has received funds to complete a pivotal clinical trial of the SCiP device in children with cerebral palsy (CP),…

Wireless brain implant for mental health treatment tested in human

A company developing an implant that stimulates neural circuits in the brain with the aim of treating mental health disorders…

PathMaker begins testing non-invasive neuromodulation device in ALS patients

PathMaker Neurosystems has started an early feasibility study investigating its non-invasive neuromodulation device in patients with amyotrophic lateral sclerosis (ALS).…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close